US FDA Panel Backs Sanofi, Isis Drug for Rare Disorder

US FDA panel backs Sanofi, Isis drug for rare disorder

Filed under: drug treatment news 2012

WASHINGTON | Thu Oct 18, 2012 4:29pm EDT. WASHINGTON (Reuters) – A U.S. Food and Drug Administration panel of outside experts recommended the Sanofi SA and Isis … "There's not a whole lot of treatment options for patients with this (disease)," the …
Read more on Reuters

PropThink: Pozen Presents Impressive Phase 3 Data At ACG

Filed under: drug treatment news 2012

On October 22, 2012, Pozen (NASDAQ:POZN) presented a full analysis of the integrated results of its two Phase 3 studies comparing PA-325/40 (EC-ASA 325 mg + IR omeprazole 40 mg) to enteric-coated aspirin (EC-ASA) 325 mg in patients requiring aspirin …
Read more on Reuters

Drug showed promise in clearing drug-resistant tuberculosis

Filed under: drug treatment news 2012

CHICAGO | Wed Oct 17, 2012 5:59pm EDT. CHICAGO (Reuters) – An antibiotic used to treat severe bacterial infections showed promise at treating a highly drug-resistant and deadly form of tuberculosis, U.S. government and South Korean researchers said on …
Read more on Reuters